{"Clinical Trial ID": "NCT00171314", "Intervention": ["INTERVENTION 1:", "Frontal zoledronic acid", "zoledronic acid 4 mg 15-minute intravenous infusion (IV) every 6 months for 5 years from day 1. All participants took Letrozole 2.5 mg/day tablets for 5 years from day 1.", "INTERVENTION 2:", "Delayed zoledronic acid", "zoledronic acid 4 mg 15 minute intravenous infusion (IV) every 6 months from the occurrence of one of the following symptoms: AMD T-score <= -2.0 SD to the lumbar spine or total hip, any clinical fracture unrelated to trauma or asymptomatic fracture discovered at the visit to month 36."], "Eligibility": ["Incorporation criteria:", "Stage I-IIIa Breast cancer", "Postmenopausal menopausal", "Recent breast cancer surgery", "- Exclusion criteria:", "Metastatic diseases", "A bilateral invasive disease", "Clinical or radiological evidence of an existing fracture in the spine or hip", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Percentage change in lumbar spine BMD (L2-L4) after 12 months of letrozole therapy", "\u00b7 Bone mineral density (BMD) is measured by dual-energy X-ray absorptiometry (DXA). Percentage change = [(BMD at visit - BMD at reference base) / BMD at reference base] * 100.", "Time limit: From reference - 12 months", "Results 1:", "Title of arm/group: Frontal zoledronic acid", "Description of the arm/group: Zoledronic acid 4 mg Intravenous infusion (IV) 15 minutes every 6 months for 5 years from day 1. All participants took Letrozole 2.5 mg/day tablets for 5 years from day 1.", "Total number of participants analysed: 254", "Average (standard deviation)", "Unit of measure: Percentage change 2,680 (2,8451)", "Results 2:", "Title of arm/group: Delayed zoledronic acid", "Description of the arm/group: Zoledronic acid 4 mg Intravenous infusion (IV) 15 minutes every 6 months from the occurrence of any of the following symptoms: T-score BMD <= -2.0 SD to the lumbar spine or total hip, any clinical fracture unrelated to trauma or asymptomatic fracture discovered at the visit to month 36.", "Total number of participants analysed: 269", "Average (standard deviation)", "Unit of measure: Percentage change -3.314 (3.9632)"], "Adverse Events": ["Undesirable Events 1:", "Total: 47/254 (18.50 per cent)", "Anemia 1/254 (0.39%)", "Febrile neutropenia 1/254 (0.39%)", "- Lymphadenopathy 1/254 (0.39%)", "- Acute myocardial infarction 1/254 (0.39%)", "Angine pectoris 0/254 (0.00 %)", "Unstable Angina 0/254 (0.00 %)", "- Left branch block of assembly 0/254 (0.00 %)", "Heart failure 4/254 (1.57%)", "Coronary artery disorders 0/254 (0.00 %)", "Coronary stenosis 1/254 (0.39%)", "Adverse Events 2:", "Total: 56/269 (20.82 per cent)", "Anemia 1/269 (0.37%)", "Febrile neutropenia 0/269 (0.00 %)", "- Lymphadenopathy 0/269 (0.00 %)", "- Acute myocardial infarction 0/269 (0.00 %)", "Angine pectoris 3/269 (1.12%)", "Unstable Angina 1/269 (0.37%)", "- Left branch block 1/269 (0.37%)", "- Heart failure 1/269 (0.37%)", "Coronary artery disorders 1/269 (0.37%)", "Coronary stenosis 0/269 (0.00 %)"]}